LIFEVANTAGE CORP Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum
LIFEVANTAGE CORP (LFVN) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum of 1.19% for the 9-month period ending 2013-03-31, per its 10-Q filed 2013-05-09.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum · last filed 2013-05-09
- LIFEVANTAGE CORP share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2012-09-30 was 0.88%, a 7.37% decline year-over-year.
- LIFEVANTAGE CORP share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2011-09-30 was 0.95%.
- LIFEVANTAGE CORP share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2012 was 1.41%, a 46.59% decline from fiscal 2011.
- LIFEVANTAGE CORP share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2011 was 2.64%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 12 month |
|---|---|---|---|---|
| 2013-03-31 | 1.19% 10-Q · filed 2013-05-09 | |||
| 2012-12-31 | 1.03% 10-Q · filed 2013-02-07 | |||
| 2012-09-30 | 0.88% 10-Q · filed 2012-11-08 | |||
| 2012-06-30 | 1.41% 10-K · filed 2012-09-10 | |||
| 2012-03-31 | 0.97% 10-Q · filed 2013-05-09 | |||
| 2011-12-31 | 0.97% 10-Q · filed 2013-02-07 | |||
| 2011-09-30 | 0.95% 10-Q · filed 2012-11-08 | |||
| 2011-06-30 | 2.64% 10-K · filed 2012-09-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |